section name header

Evidence summaries

ACE Inhibitors for Secondary Prevention after Myocardial Infarction in Patients with Left Ventricular Dysfunction

ACE inhibitors reduce mortality, hospitalisation for congestive heart failure, and recurrent non-fatal myocardial infarction in people with left ventricular dysfunction after myocardial infarction. Level of evidence: "A"

A topic in Clinical Evidence 1 summarizes the evidence on ACE inhibitors in patients with myocardial infarction and left ventricular dysfunction. A systematic review of 3 RCTs (5 966 people). ACE inhibitors significantly reduced mortality (OR 0.74, 95% CI 0.66 to 0.83, NNT 17 during 2 years), hospitalisation for congestive heart failure (OR 0.73, 95% CI 0.63 to 0.85, NNT 28) and recurrent non-fatal myocardial infarction (OR 0.80, 95% CI 0.69 to 0.94, NNT 43).

The following decision support rules contain links to this evidence summary:

References

  • Sudlow C, Lonn E, Pignone M, Ness A, Rihal C. Secondary prevention of ischaemic cardiac events. Clin Evid 2002 Jun;(7):124-60. [PubMed]

Primary/Secondary Keywords